Lipopeptide-containing composition and application thereof

Abstract

The invention relates to the field of bacteriostatic agents, and discloses a lipopeptide-containing composition and application thereof, the composition comprises lipopeptide and cofactors, and the cofactors comprise at least one of nisin, gluconate, a first component and nipagin ester and / or sodium salt thereof; the first component is at least one of dehydroacetic acid, dehydroacetate, sorbic acid, sorbate, propionate and polylysine; on the basis of the total weight of the composition, the content of the nipagin ester and / or the sodium salt is less than or equal to 10wt%. Compared with antibiotics, the lipopeptide-containing composition provided by the invention has the advantages that the antibacterial effect is equivalent or better, and the lipopeptide-containing composition is friendly to animals and environment and non-toxic; the growth of the ethanol fermentation strain (such as saccharomyces cerevisiae) and the production of ethanol are not influenced, and the growth of the ethanol fermentation strain and the production of ethanol can also be promoted in a specific implementation mode.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of bacteriostatic agents, in particular to a lipopeptide-containing composition and application thereof. BACKGROUND

[0002] At present, environmental protection is continuing and spreading, and in the face of increasingly strict restrictions on the use of antibiotics, antibiotic substitutes have developed like mushrooms after rain. At present, microecological preparations, enzyme preparations, antibacterial peptides and traditional Chinese medicines are mainly represented.

[0003] However, these antibiotic substitutes still have some limitations in specific use. For example, the use conditions of microecological preparations are relatively strict and cannot be applied to various working scenes; pure enzyme preparations cannot achieve the use effect of antibiotics and have relatively high cost; antibacterial peptides have wide sources, many types, small molecular weight, low content in nature, difficult separation and purification, and high cost of chemical synthesis; and some traditional Chinese medicine extracts have problems of resource shortage, unstable efficacy and quality, and high cost.

[0004] Broad-spectrum bacteriostasis and wide use range have become key difficulties to be solved for antibiotic substitutes. SUMMARY

[0005] The purpose of the present application is to overcome the above-mentioned problems in the prior art, provide a lipopeptide-containing composition and application thereof, the lipopeptide-containing composition has a relatively wide bacteriostatic spectrum, has a bacteriostatic effect equivalent to or better than that of antibiotics, is friendly to animals and the environment, can be applied to the fields of food, industry, cosmetics, medicine and the like, and has a relatively wide application range.

[0006] In order to achieve the above-mentioned purpose, the present application provides a lipopeptide-containing composition in one aspect, the composition comprises: a lipopeptide and an auxiliary factor, the auxiliary factor comprises at least one of nisin, gluconate, a first component and a nipagin ester and / or sodium salt thereof;

[0007] The first component is at least one of dehydroacetic acid, dehydroacetic acid salt, sorbic acid, sorbic acid salt, propionic acid salt and polylysine;

[0008] The content of the nipagin ester and / or sodium salt is ≤10 wt% based on the total weight of the composition.

[0009] The second aspect of the present application provides application of the above-mentioned composition in fermentation and / or food bacteriostasis.

[0010] Compared with antibiotics, the composition containing lipopeptide provided by the application has equivalent or better bacteriostatic effect; the composition of the application has excellent inhibitory performance on miscellaneous bacteria and does not affect the growth of ethanol fermentation strains (such as Saccharomyces cerevisiae) and ethanol production, and in specific embodiments, can promote the growth of ethanol fermentation strains, thereby promoting ethanol production; in addition, the composition containing lipopeptide provided by the application is friendly to animals and the environment and has no toxicity and harm compared with antibiotics. BRIEF DESCRIPTION OF DRAWINGS

[0011] Figure 1 is a data graph of chromatographic total residual sugar and residual reducing sugar of samples after fermentation for 66h, in which the composition containing lipopeptide prepared in Examples 1-6 and Comparative Examples 1-4 and antibiotics are used as raw materials for liquefied mash with serious factory pollution;

[0012] Figure 2 is a data graph of chromatographic organic acid of samples after fermentation for 66h, in which the composition containing lipopeptide prepared in Examples 1-6 and Comparative Examples 1-4 and antibiotics are used as raw materials for liquefied mash with serious factory pollution;

[0013] Figure 3 is a data graph of ethanol / glycerol of samples after fermentation for 66h, in which the composition containing lipopeptide prepared in Examples 1-6 and Comparative Examples 1-4 and antibiotics are used as raw materials for liquefied mash with serious factory pollution. DETAILED DESCRIPTION

[0014] The endpoints of the ranges and any values disclosed herein are not limited to the precise values stated. The endpoints of the ranges and any values are understood to be approximate values. The exact numerical values of the endpoints of the ranges and the separate points are not to be construed as limiting. Ranges can be expressed in a variety of ways. For example, a range of "between A and B" can be expressed as greater than A and less than B; as greater than or equal to A and less than B; as greater than A and greater than or equal to B; or as greater than or equal to A and greater than or equal to B. Language such as "up to" can indicate a range of "0 to A", where A is a value. These and other forms should be considered within the scope of the ranges disclosed herein.

[0015] In one aspect, the application provides a composition containing lipopeptide, which comprises: lipopeptide and a cofactor, wherein the cofactor comprises at least one of nisin, gluconate, a first component, and a nipagin ester and / or sodium salt thereof.

[0016] The first component is at least one of dehydroacetic acid, dehydroacetic acid salt, sorbic acid, sorbic acid salt, propionic acid salt, and polylysine.

[0017] The content of the nipagin ester and / or sodium salt is ≤10% by weight, based on the total weight of the composition.

[0018] In this invention, the lipopeptide can be derived from plants, animals, or microorganisms, preferably microorganisms, more preferably bacteria, most preferably Bacillus microorganisms, further preferably Bacillus subtilis, and even more preferably, the accession number is CGMCCNO.8906, and the publication number is CN103898038A.

[0019] Preferably, the lipopeptide is a cyclic lipopeptide and / or a linear lipopeptide; more preferably, the lipopeptide includes at least one of structural formulas I, II and III;

[0020] Where R is C 10-17 Alkyl groups, A1, A2, A3…A m These are the 1st, 2nd, 3rd...mth amino acids on the peptide chain, where m is 6-20 and is an integer, and n is 1-17 and is an integer; in this invention, the carboxyl group of the fatty acid is attached to the N-terminus of A1, A... m The C-terminal carboxyl group is linked to the hydroxyl or amino groups of fatty acids or other amino acids on the peptide chain to form a cyclic structure. The linear lipopeptide refers to the linear product formed after the ring-opening of a cyclic lipopeptide. 10-17 Alkyl groups can be straight-chain or branched.

[0021] In this invention, A1→A2→A3→…→A mGlu→ Val / Leu / Ile→ Leu→ Ala / Val / Leu / Ile→ Asp→ Leu→ Val / Leu / Ile, Glu→ Leu→ Met→ Leu→ Pro→ Leu→ Leu→ Leu, Gln / Glu→ Leu / Ile→ Leu→ Val / Ile→ Asp→ Leu→ Val / Ile, Glu→ Leu→ Leu→ Leu→ Asp→ Leu→ Val / Ile, Asn→ Tyr→ Asn→ Gln→ Pro→ Asn→ Ser, Asp→ Tyr→ Asn→ Gln→ Pro→ Asn→ Ser, Asn→ Tyr→ Asn→ Pro→ Glu→ Ser→ Thr, Asn→ Tyr→ Asn→ Gln→ Pro→ Asn→ Thr, Asn→ Tyr→ Asn→ Ser→ Glu→ Ser→ Thr, Asn→ Tyr→ Asn→ Gln→ Pro→ Ser→ Asn, Glu→ Orn→ Tyr→ Thr→ Glu→ Ala→ Pro→ Gln→ Tyr→ Ile, Glu→ Orn→ Tyr→ Thr→ Glu→ Val→ Pro→ Gln→ Tyr→ Ile, Glu→ Orn→ Tyr→ Thr→ Glu→ Ala→ Pro→ Gln→ Tyr→ Ile, Glu→ Orn→ Tyr→ Thr→ Glu→ Val→ Pro→ Gln→ Tyr→ Ile, or Thr→ Gly→ Ala→ Ser→ His→ Gln→ Gln.

[0022] Preferably, the lipopeptide is at least one of the surfactin family, the iturin family, and the fengycin; more preferably, the lipopeptide is at least one of surfactin, iturin, fengycin, lichenysin, bactobelin, pumilacidin, bacillomycin, subtilimicin, arthrofactin, mycosubtilin, kurstakin, subtilin, polymyxin, octapeptin, and colicin.

[0023] In the present application, the lipopeptide is obtained by culturing the microorganism (as described above) in a fermentation medium at 30-37°C, 150-250rpm for 2-6 hours, then adding 0.5-1.5mM IPTG (isopropyl-β-D-thiogalactopyranoside) and continuing to culture for 1-3 days to obtain a fermentation broth containing the lipopeptide. The pH of the fermentation broth is adjusted to be acidic, and the lipopeptide forms a precipitate. The precipitate is dried to obtain the lipopeptide product. The microorganism can also be activated by culturing in LB liquid medium at 30-37°C for 12-20h, then inoculating the fermentation medium at a ratio of 3-7% (volume / volume, based on the fermentation medium).

[0024] In the present application, the fermentation medium used has the following composition: 30-100 g / L of sugar (such as at least one of glucose, sucrose, fructose, lactose, maltose and dextrin), 10-50 g / L of inorganic nitrogen source, 0.5-3 g / L of yeast extract, 0.1-1 g / L of KH2PO4, 0.5-0.3 g / L of Na2HPO4·12H2O, 0.002-0.01 g / L of CaCl2, 0.002-0.01 g / L of MnSO4·H2O, 0.002-0.01 g / L of FeSO4·7H2O, and pH 6.5-7.5. The inorganic nitrogen source is preferably an ammonium salt, more preferably urea and / or ammonium sulfate.

[0025] In the present application, the auxiliary factor is not particularly limited, and is preferably an agent that can cooperate with the lipopeptide to exert an antibacterial effect and is friendly to animals and the environment. The content of the auxiliary factor in the composition is not less than 1% by weight.

[0026] More preferably, the weight ratio of the lipopeptide to the auxiliary factor is 1:0.009-99, which can be 1:0.009, 1:0.01, 1:0.1, 1:0.25, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:25, 1:30, 1:35, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:99, or a range formed by any two of the above values and values within the range, and most preferably 1:0.25-19.

[0027] The present inventors have found that when the auxiliary factor is nisin, gluconate (such as sodium gluconate), at least one of the first component and the nipagin ester and / or sodium salt thereof, the antibacterial effect thereof can be comparable to or better than that of antibiotics, and the effect on ethanol yield during fermentation is comparable to or improved over that of antibiotics.

[0028] The present inventors have found that when the composition includes the nipagin ester and / or sodium salt thereof, the content of the nipagin ester and / or sodium salt thereof is ≤10% by weight based on the total weight of the composition, which is more conducive to the efficient utilization of sugar by Saccharomyces cerevisiae and fermentation under better antibacterial effect. Preferably, the content of the nipagin ester and / or sodium salt thereof is 3-8% by weight based on the total weight of the composition (which can be 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, or a range formed by any two of the above values and values within the range), which is even better.

[0029] The inventors of the present invention found that the weight ratio of each agent in the auxiliary factor to the lipopeptide affects the antibacterial property of the composition and the effect on the ethanol production during the fermentation of the liquefied mash differently when the auxiliary factor is different.

[0030] Preferably, when the composition comprises nisin, the weight ratio of nisin to the lipopeptide is 0.01-20, which can be 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.08, 0.1, 0.3, 0.5, 0.7, 0.9, 1, 1.2, 1.4, 1.6, 1.8, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or a range formed by any two of the above values and the values within the range, more preferably 0.06-2, and the effect is the best within the range.

[0031] Preferably, when the composition comprises gluconate, the weight ratio of gluconate to the lipopeptide is less than or equal to 5, more preferably 0.01-5, which can be 0.01, 0.03, 0.04, 0.05, 0.1, 0.2, 0.3, 0.5, 0.7, 0.9, 1, 1.2, 1.4, 1.6, 1.8, 2, 3, 2.2, 2.4, 2.6, 2.8, 3, 3.2, 3.4, 3.6, 3.8, 4, 4.2, 4.4, 4.6, 4.8, 5 or a range formed by any two of the above values and the values within the range, and the effect is the best within the range.

[0032] Preferably, when the composition comprises the first component, the weight ratio of the first component to the lipopeptide is less than 80, which can be 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.08, 0.1, 0.3, 0.5, 0.7, 0.9, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or a range formed by any two of the above values and the values within the range, more preferably 0.06-16, and the effect is the best within the range.

[0033] Preferably, when the composition comprises nipagin and / or its sodium salt, the weight ratio of nipagin and / or its sodium salt to the lipopeptide is less than 10, which can be 0.01, 0.03, 0.05, 0.07, 0.09, 0.1, 0.3, 0.5, 0.7, 0.9, 1, 1.1, 1.3, 1.5, 1.7, 1.9, 2, 3, 4, 5, 6, 7, 8, 9 or a range formed by any two of the above values and the values within the range, more preferably 0.03-1.3, and the effect is the best within the range. The nipagin is not limited and can be at least one of nipagin methyl ester, nipagin ethyl ester and nipagin propyl ester, more preferably nipagin methyl ester.

[0034] The inventors of the present application found that when the co-factor is nisin, gluconate (such as sodium gluconate), dehydroacetate (such as sodium dehydroacetate) and nipagin methyl ester, the obtained composition has the best antibacterial effect, and is more beneficial to the high-efficiency utilization of sugar by Saccharomyces cerevisiae and fermentation in the fermentation process, and has a higher ethanol yield. Preferably, when the weight ratio of the gluconate to nisin is 1:0.25-12, which can be 1:0.25, 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12 or a range formed by any two of the above values and values within the range, preferably 1:1.5-6, and when the weight ratio of the gluconate to the dehydroacetate is 1:0.5-85, which can be 1:0.5, 1:1, 1:1.5, 1:2, 1:3, 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80, 1:85 or a range formed by any two of the above values and values within the range, preferably 1:3-50, and when the weight ratio of the gluconate to the nipagin methyl ester is 1:0.75-8, which can be 1:0.75, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:3.5, 1:4, 1:5, 1:6, 1:7, 1:8 or a range formed by any two of the above values and values within the range, preferably 1:2-6, the effect is the best.

[0035] In the present application, the gluconate can be an alkali metal gluconate and / or an alkaline earth metal gluconate commonly used in the art, preferably sodium gluconate.

[0036] In the present application, the dehydroacetate can be an alkali metal dehydroacetate and / or an alkaline earth metal dehydroacetate commonly used in the art, preferably sodium dehydroacetate.

[0037] The second aspect of the present application provides a use of the above-mentioned composition in fermentation and / or food antibacterial, in particular in inhibiting the growth of miscellaneous bacteria in the ethanol fermentation process and / or improving the sugar utilization capacity of the ethanol fermentation strain.

[0038] In the present application, the miscellaneous bacteria can be at least one of gram-positive bacteria, gram-negative bacteria, actinomycetes, molds and other fungi.

[0039] The application will be described in detail below by examples. In the following examples, the surfactin is obtained by activating Bacillus subtilis THY-7 (CGMCC NO. 8906, published as CN103898038A) by 16h culture in LB liquid medium, then adding 5% (based on the fermentation medium) into the fermentation medium, and culturing at 37℃, 200rpm for 4h, then adding 1mM IPTG, and continuing to culture for 2 days to obtain the fermentation broth containing surfactin. The pH of the fermentation broth is adjusted to be acidic, and the surfactin forms a precipitate. The solid-liquid separation and drying obtain the surfactin product.

[0040] The composition of the fermentation medium used is: glucose 50g / L, ammonium sulfate 30g / L, yeast extract powder 1.5g / L, KH2PO40.5g / L, Na2HPO4·12H2O 0.4g / L, CaCl20.006g / L, MnSO4·H2O 0.006g / L, FeSO4·7H2O 0.006g / L, pH 7;

[0041] Glucose and ammonium sulfate are purchased from National Pharmaceutical Group Chemical Reagent Co., Ltd.;

[0042] Yeast extract powder FM888 is purchased from Angel Yeast Co., Ltd.;

[0043] Angel super distiller's dry yeast and acid protease are both purchased from Angel Yeast Co., Ltd., and glucoamylase is purchased from Shandong Longda Biological Engineering Co., Ltd.;

[0044] Nisin is a commercially available product of Zhejiang Yinao Biological Technology Co., Ltd., and is food grade;

[0045] Sodium gluconate is a commercially available product of Shandong Baisheng Biological Technology Co., Ltd., and is food grade;

[0046] Sodium dehydroacetate is a commercially available product of Shandong Shengxie Biological Technology Co., Ltd., and is food grade;

[0047] Nipagin M is a commercially available product of Shengyuan Food Raw Material Co., Ltd., and is food grade;

[0048] Antibiotic product (penicillin) is a commercially available product of Shandong Naobe Biological Technology Co., Ltd., and is food grade.

[0049] Examples 1-6 and Comparative Examples 1-4

[0050] The components are added in the order of the content in Table 1, and mixed uniformly to prepare the lipopeptide-containing composition.

[0051] Table 1

[0052]

[0053] Note: The units of the values in the table are wt%

[0054] Test Example:

[0055] This test example is to carry out fermentation experiments with the actual factory seriously contaminated liquefied mash (liquefied mash produced without sterilization in the ethanol production process) as raw material:

[0056] 1. Yeast culture

[0057] Step 1, take 500ml conical flask, weigh 8g dry yeast, add 200mL activated water, 35℃ incubator activation for 20 minutes, get activated liquid;

[0058] Step 2, use seriously contaminated liquefied mash (pH 4.2) to culture the yeast, add 2.5ml activated liquid per 200g liquefied mash in a 500mL conical flask;

[0059] Step 3, add corresponding bacteriostatic agent 6.7mg, acid protease 0.04g, glucoamylase 0.026g to the yeast, culture the yeast under ventilation, 30℃, 45rpm, culture for 10h, get the yeast. The specific addition type and amount are shown in Table 2.

[0060] Table 2

[0061]

[0062] 2. Fermentation

[0063] Step 1, take 287g seriously contaminated liquefied mash (pH 4.2) to a 1000mL conical flask, add 63g of yeast obtained in step 1, at this time the concentration of bacteriostatic agent in the fermentation broth is: 6mg / L of antibiotic product for the control group, and 6mg / L of the composition prepared in Examples 1-6 and Comparative Examples 1-4 for the experimental groups.

[0064] Step 2, add 0.038g glucoamylase to each bottle, seal with a liquid seal tube, mix at a speed of 100rpm, the fermentation temperature is 32℃, the fermentation time is 66h; each group of experiments has three parallel samples, the specific addition type and amount are shown in Table 3.

[0065] Step 3, after fermentation is completed, dilute the mature mash to prepare liquid samples;

[0066] Step 4, detect the sugar content, organic acids, glycerol, ethanol and other substances in the mature mash by liquid phase column Aminex HPX–87H (purchased from Agilent, model 300x 7.8mm), calculate the average value of the experimental data of 3 parallel samples in each group, the results are shown in Table 4.

[0067] Table 3

[0068]

[0069] Table 4

[0070]

[0071]

[0072] Generally, chromatography residual total sugar and chromatography residual reducing sugar are used to characterize whether the fermentation is complete. Generally, the higher the chromatography residual total sugar and residual reducing sugar, the less complete the fermentation. Chromatography residual total sugar = DP4+ (oligosaccharides above maltotetraose and below decasaccharides) + DP3 (maltotriose) + DP2 (maltose) + glucose + fructose, and chromatography residual reducing sugar = DP3 + glucose + fructose. From Table 3, it can be seen that the chromatography residual total sugar and chromatography residual reducing sugar of Examples 3-5 are the lowest, with chromatography residual total sugar of 0.71 g / 100 mL, 0.72 g / 100 mL and 0.69 g / 100 mL, respectively, and chromatography residual reducing sugar of 0.1 g / 100 mL, 0.11 g / 100 mL and 0.11 g / 100 mL, respectively, all of which are lower than the values of the antibiotic product (chromatography residual total sugar 0.76 g / 100 mL, chromatography residual reducing sugar 0.13 g / 100 mL). Figure 1

[0073] Chromatography organic acid is used to characterize the degree of fermentation contamination. The larger the chromatography organic acid value, the more serious the fermentation contamination, i.e., the weaker the inhibition of the bacteriostatic agent on the miscellaneous bacteria. Chromatography organic acid = lactic acid + acetic acid. From Table 4, it can be seen that the chromatography organic acid of Examples 3-5 is the lowest, with values of 0.33 g / 100 mL, 0.32 g / 100 mL and 0.36 g / 100 mL, respectively, all of which are lower than the value of the antibiotic product group (0.37 g / 100 mL). Figure 2

[0074] Ethanol / glycerol is used to characterize the fermentation effect. The larger the ethanol / glycerol value, the higher the fermentation utilization rate. From Table 5, it can be seen that the ethanol / glycerol value of Examples 3-5 is the highest, with values of 11.89, 12.42 and 12.84, respectively, which are much higher than the value of the antibiotic product group (10.26). The ethanol / glycerol values of Examples 2 and 6 are basically the same as those of the antibiotic group. Figure 3

[0075] ​​​Therefore, it is illustrated that the lipopeptide-containing compositions of Examples 3-5 are more conducive to the efficient utilization of sugar and fermentation of the super yeast than the antibiotic products in achieving better antibacterial effect; the lipopeptide-containing composition of Example 6 is slightly weaker than the antibiotic product, but basically does not affect the normal fermentation of the super yeast; the lipopeptide-containing compositions of Comparative Examples 1-4 are less conducive to the fermentation of the super yeast than the antibiotic products due to the poor inhibitory effect on the contaminating bacteria.

[0076] It can be seen from the results of the test examples that, compared with the antibiotic product, the lipopeptide-containing composition of the present application can better inhibit the contaminating bacteria under actual working conditions. Therefore, it can be seen that the lipopeptide-containing composition of the present application can partially or completely replace the antibiotic, and if applied to fuel ethanol production enterprises, on the one hand, it meets the demand of antibiotic replacement, and on the other hand, it is conducive to cost reduction and efficiency increase of fuel ethanol enterprises.

[0077] 3. Effect of the bacteriostatic agent on yeast growth

[0078] The liquefied mash with serious contamination in the production line was sterilized at 115℃ for 30min, and then the yeast mother culture was carried out according to the steps of Test Example 1, three parallel experiments were carried out for each group, and the yeast count was carried out. The specific amount of the added substance in the sterilized liquefied mash and the average number of yeast are shown in Table 5. It is found that the yeast number of Examples 1-6 is higher than that of the blank control without adding the bacteriostatic agent, and the yeast number of the penicillin experimental group is basically consistent with that of the blank control. Therefore, it can be seen that the components in the bacteriostatic agent do not have adverse effects on the growth of yeast.

[0079] Table 5

[0080]

[0081] The preferred embodiments of the present application are described in detail above, but the present application is not limited thereto. Within the technical concept of the present application, various simple modifications can be made to the technical solutions of the present application, including the combination of various technical features in any other suitable manner. These simple modifications and combinations should also be considered as disclosed by the present application and fall within the protection scope of the present application.

Claims

1. A composition containing lipopeptides, characterized in that, The composition comprises: lipopeptides and cofactors, wherein the cofactors include at least one of nisin, gluconate, a first component, and parabens and / or their sodium salts; The first component is at least one selected from dehydroacetic acid, dehydroacetate, sorbic acid, sorbate, propionate, and polylysine; Based on the total weight of the composition, the content of the parabens and / or sodium salt is ≤10% by weight.

2. The composition according to claim 1, wherein, Based on the total weight of the composition, the content of parabens and / or their sodium salt is 3-8% by weight; And / or, the content of the cofactor in the composition is not less than 1% by weight; And / or, the lipopeptide is a cyclic lipopeptide and / or a linear lipopeptide; Preferably, the lipopeptide comprises at least one of structural formulas I, II and III; Where R is C 10-17 Alkyl groups, A1, A2, A3…A m These are the 1st, 2nd, 3rd...mth amino acids on the peptide chain, where m is 6-20 and is an integer, and n is 1-17 and is an integer. Preferably, the lipopeptide is at least one of the surfactant family, the iturobrine family, and fenbufen; Preferably, the lipopeptide is at least one of surfactant, irisin, fenbufen, lichenin, babylin, permiracin, spore-forming mycotoxin, antifungal mycotoxin, phosphatidylcholine, fusarium oxytocin, kurstakin, spore-forming mycotoxin, polymyxin, octapeptide, and polypeptide mycotoxin.

3. The composition according to claim 1 or 2, wherein, The weight ratio of the lipopeptide to the cofactor is 1:0.009-99, preferably 1:0.25-19.

4. The composition according to claim 1 or 2, wherein, The composition includes nisin, wherein the weight ratio of nisin to lipopeptide is 0.01-20, preferably 0.06-2.

5. The composition according to claim 1 or 2, wherein, The composition comprises gluconate, wherein the weight ratio of gluconate to lipopeptide is less than or equal to 5, preferably 0.01-5; And / or, the gluconate is sodium gluconate; And / or, the dehydroacetate is sodium dehydroacetate.

6. The composition according to claim 1 or 2, wherein, The composition includes a first component, wherein the weight ratio of the first component to the lipopeptide is less than 80, preferably 0.06-16.

7. The composition according to claim 1 or 2, wherein, The composition comprises parabens and / or their sodium salts, wherein the weight ratio of the parabens and / or their sodium salts to the lipopeptide is less than 10, preferably 0.03-1.

3.

8. The composition according to claim 1 or 2, wherein, The paraben is at least one of methylparaben, ethylparaben, and propylparaben, preferably methylparaben.

9. The composition according to claim 1 or 2, wherein, The cofactors are gluconate, nisin, dehydroacetate, and methylparaben; Preferably, the weight ratio of gluconate, nisin, dehydroacetate and methylparaben is 1:0.25-12:0.5-85:0.75-8, and more preferably 1:1.5-6:3-50:2-6.

10. The use of the composition according to any one of claims 1-9 in fermentation and / or food antibacterial applications.

Images